Brief: Ryvu Therapeutics Partner Menarini Group Receives FDA Orphan Drug Designation

Ryvu Therapeutics SA

04/11/2021 14:44

Nov 4 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * RYVU'S PARTNER, MENARINI GROUP RECEIVES FDA ORPHAN DRUG
DESIGNATION FOR SEL24 (MEN1703) FOR TREATMENT OF ACUTE MYELOID
LEUKEMIA (AML)
    * CURRENTLY SEL24/MEN1703 IS BEING EXAMINED AS PART OF
DIAMOND-01
TRIAL AS A SINGLE AGENT FOR TREATMENT OF PATIENTS WITH AML

Source text for Eikon:  ID:nEM81KTlBa 
Further company coverage:  RVU.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))